Sen. Ron Wyden (D-Ore.) is criticizing Biogen (NASDAQ:BIIB) for its estimated $56K annual price tag for its newly approved Alzheimer's treatment …
Full story here.
Originally published 2021-06-08 09:46:15 — seekingalpha.com
Visited 1 times, 1 visit(s) today
